Qsam doses first patient in Cyclosam clinical trial

By AuntMinnie.com staff writers

April 29, 2022 -- Qsam Biosciences said the first patient has begun treatment in the company's clinical trial evaluating samarium-153-DOTMP (CycloSam) for the treatment of bone cancer and related diseases.

The study is a phase I open-label, dose-escalation trial to assess the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam. Patients with cancer that originated in the bone including osteosarcoma and Ewing's sarcoma are also eligible to participate.

Copyright © 2022 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking